What Does the Research Show About CJC-1295 DAC vs No DAC?
CJC-1295 DAC and CJC-1295 No DAC are related GHRH-based compounds with different structural features. Published CJC-1295 research has mainly examined the long-acting DAC compound, including its structure, plasma persistence, and measured GH and IGF-1 responses.
The evidence is not equally developed for both forms. The main human studies investigated the long-acting CJC-1295 compound rather than conducting a direct DAC versus No DAC comparison.
CJC-1295 DAC vs No DAC: Terminology
CJC-1295 DAC refers to the long-acting CJC-1295 compound described in the foundational research. The original research characterized it as a modified GHRH(1-29) analogue containing an additional C-terminal modification.
CJC-1295 No DAC is commonly used to describe a related non-DAC compound, often referred to as Modified GRF(1-29).
This terminology is important when reviewing the literature. The principal published human studies identified for CJC-1295 examined the long-acting compound. They were not direct studies comparing DAC with No DAC.
Structural Difference Between CJC-1295 DAC and No DAC
The main structural distinction is the additional modification present in CJC-1295 DAC.
Preclinical research described CJC-1295 as a tetrasubstituted GHRH(1-29) analogue containing an Nε-3-maleimidopropionamide derivative of lysine at the C terminus. The study also examined its association with serum albumin and its plasma persistence.
The compound commonly described as CJC-1295 No DAC does not contain this additional DAC modification.
CJC-1295 DAC vs No DAC: Key Research Differences
| Research Characteristic | CJC-1295 DAC | CJC-1295 No DAC |
|---|---|---|
| Research terminology | Long-acting CJC-1295 compound described in the foundational studies | Common term for a related non-DAC compound, generally referred to as Modified GRF(1-29) |
| DAC modification | Present | Absent |
| C-terminal modification | Contains the additional C-terminal modification described in the original research | Does not contain the DAC modification |
| Albumin association | Examined in the original CJC-1295 research | Not established by the principal CJC-1295 human studies |
| Human pharmacokinetic research | Published human data are available | Direct comparable human data are limited |
| Human GH research | Examined in controlled human studies | Direct comparable human data are limited |
| Human IGF-1 research | Examined in controlled human studies | Direct comparable human data are limited |
| Direct human DAC vs No DAC study | Not established in the principal studies | Not established in the principal studies |
The table reflects the distinction in the published evidence. It does not assume that findings from one compound apply to the other.
Pharmacokinetic Findings
The original preclinical research examined the plasma persistence of CJC-1295. The compound remained detectable in rat plasma beyond 72 hours, and a CJC-1295-related species was detected at the serum albumin band.
A later randomized, placebo-controlled human study examined the pharmacokinetics of the long-acting CJC-1295 compound in healthy adults and reported prolonged exposure.
These findings describe the compound investigated in those studies. They do not establish the pharmacokinetic profile of CJC-1295 No DAC.
Human GH and IGF-1 Findings
The main human evidence comes from studies of the long-acting CJC-1295 compound.
A randomized, placebo-controlled study in healthy adults reported dose-dependent increases in mean plasma GH and IGF-1 concentrations following exposure to CJC-1295.
A separate human study examined GH secretion patterns after CJC-1295 exposure. The study reported increased mean and trough GH concentrations while pulsatile GH secretion remained present. It also reported increased IGF-1 concentrations.
These observations apply to the compound investigated in those studies. They do not establish the same GH or IGF-1 findings for CJC-1295 No DAC.
Is There a Direct Human Comparison Between DAC and No DAC?
The principal published human studies do not provide a direct controlled comparison between CJC-1295 DAC and CJC-1295 No DAC.
The human research examined the long-acting CJC-1295 compound and measured pharmacokinetic and hormonal endpoints. The studies were not designed to test both forms under identical experimental conditions.
Therefore, the available research cannot establish whether the two forms produce equivalent or different GH, IGF-1, or pharmacokinetic responses.
What Is Known About CJC-1295 No DAC?
Direct evidence for CJC-1295 No DAC is more limited than the published evidence for the long-acting CJC-1295 compound.
The principal human studies discussed above investigated the long-acting compound. They do not provide a direct human pharmacokinetic or pharmacodynamic profile for the non-DAC form.
For this reason, findings from those studies should not be presented as direct findings for Modified GRF(1-29) or another compound described as CJC-1295 No DAC.
Limitations of the Current Evidence
The main limitation is the lack of a direct DAC versus No DAC comparison in the principal human research.
The published human studies involved healthy adults and examined specific pharmacokinetic and hormonal endpoints.
Another limitation is terminology. CJC-1295 No DAC is commonly used for a related non-DAC compound, while the foundational CJC-1295 research describes the long-acting compound.
This makes it important to identify the exact compound investigated before applying a published finding.
Conclusion
CJC-1295 DAC and CJC-1295 No DAC are related compounds with different structural features.
The published human evidence is primarily based on the long-acting CJC-1295 compound. Those studies provide information about its pharmacokinetics and measured GH and IGF-1 responses.
The principal studies do not provide a direct human DAC versus No DAC comparison. Research findings should therefore be attributed to the specific compound examined in each study rather than treated as evidence for both forms.
FAQs
References
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. PubMed ↗
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PubMed ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. PubMed ↗
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009 Dec;19(6):471-7. PubMed ↗
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. PubMed ↗
